PTGX FY2025 SEC EDGAR DEF 14A #101 of 168 in industry

Protagonist Therapeutics, Inc CEO pay ratio

The CEO earned $12.9M in FY2025 against median worker pay of $428,422 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-28
Industry
Chemicals & Pharmaceuticals
Industry rank
#101/168

Data updated August 2026

Subscribe to Protagonist Therapeutics, Inc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
30:1
Below Average (Scale: 0–1000:1)
CEO pay
$12.9M
Median worker
$428,422

Answer first

Protagonist Therapeutics, Inc's FY2025 CEO total of $12.9M ranks #385 of 1,423 complete filings; its 30:1 pay ratio ranks #1132. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $428,422. Industry placement uses the FY2025 SIC-28 peer cohort (# 101 of 168, 40th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#385
$12.9M of 1,423 FY2025
Ratio rank
#1132
30:1 of 1,423
Industry pct
40th
below the industry median pay ratio

How Protagonist Therapeutics, Inc ranks nationally

Protagonist Therapeutics, Inc CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$12,852,660 Top 27% higher than 73% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). This entry sits in this band. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Protagonist Therapeutics, Inc vs. Chemicals & Pharmaceuticals peers

CEO total pay ($12.9M) against pay ratio (30:1) for Protagonist Therapeutics, Inc (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both3149280.95861815.4857435011286884.513999419.128.4:131.9:135.5:139.1:142.6:1CEO total payPay ratio (CEO : median worker)Protagonist Therapeutics, Inc, CEO total pay: 12852660 · Pay ratio (CEO : median worker): 30:1Protagonist Therapeutics, IncAlkermes plc., CEO total pay: 8002710 · Pay ratio (CEO : median worker): 30:1Alkermes plc.Janux Therapeutics, Inc., CEO total pay: 13506231 · Pay ratio (CEO : median worker): 30:1Janux Therapeutics, Inc.Green Plains Inc., CEO total pay: 3642469 · Pay ratio (CEO : median worker): 31:1Green Plains Inc.Iovance Biotherapeutics, Inc., CEO total pay: 4755679 · Pay ratio (CEO : median worker): 31:1Iovance Biotherapeutics, Inc.Structure Therapeutics Inc., CEO total pay: 8520403 · Pay ratio (CEO : median worker): 29:1Structure Therapeutics Inc.
Protagonist Therapeutics, Inc vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Protagonist Therapeutics, Inc's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Protagonist Therapeutics, Inc

Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
30:1
FY2025
vs prior FY
-5:1
from FY2024 35:1
CEO $ YoY
+34%
$12.9M latest
Filings shown
2
FY2024–2025
Protagonist Therapeutics, Inc CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2024 $9.6M - $273,222 35:1 -
2025 $12.9M +34% $428,422 30:1 -5:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1377121, FY2024–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
30:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$12.9M
Companies in Industry
168
vs. Industry Median
Below
#101 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Protagonist Therapeutics, Inc: MODEST · HEAVY pay ratio

Protagonist Therapeutics, Inc's 30:1 ratio ranks #1132 of 1,423 FY2025 complete filings (lower third by ratio). the CEO earned 30× the median employee ($428,422) in FY2025.

Median employee $428,422 (ELITE-MED); MODEST · HEAVY stamps put about 30 median-wage years per CEO year.

CEO Total Pay

$12.9M

FY2025 Summary Compensation, above median

Pay Ratio

30:1

Below typical

Protagonist Therapeutics, Inc in the lower-ratio third

Protagonist Therapeutics, Inc's 30:1 ratio ranks #1132 of 1,423 FY2025 complete filings (lower third by ratio). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Protagonist Therapeutics, Inc's $12.9M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #385 and ratio rank #1132 split - treat 30:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$12.9M
Median Employee Pay
$428,422
Pay Ratio
30:1
Filing Date
2026-04-28

Company Info

Ticker
PTGX
CIK
1377121
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1377121, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Protagonist Therapeutics, Inc's 30:1 ratio ranks #1132 of 1,423 FY2025 complete filings (lower third by ratio).

Read with Protagonist Therapeutics, Inc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

NextDecade Corp · HEAVY

ABS(ceo_total_comp) peer at $12.9M (Δ $6K heavier vs Protagonist Therapeutics, Inc); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Genuine Parts Co · HEAVY

ABS(ceo_total_comp) peer at $12.9M (Δ $11K heavier vs Protagonist Therapeutics, Inc); HIGH · LOW-MED vs this page's MODEST · HEAVY · ELITE-MED.
S&P Global Inc. · HEAVY

ABS(ceo_total_comp) peer at $12.8M (Δ $22K lighter vs Protagonist Therapeutics, Inc); HIGH · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Agilent Technologies, Inc. · HEAVY

ABS(ceo_total_comp) peer at $12.8M (Δ $25K lighter vs Protagonist Therapeutics, Inc); STEEP · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Alkermes plc. (SIC 28 pole)

Alkermes plc. stamps MODEST · HEAVY nearest in-SIC by ABS(pay_ratio) to Protagonist Therapeutics, Inc's MODEST filing.
National dual ranks · #385/#1132

Protagonist Therapeutics, Inc's FY2025 package sits #385 by CEO dollars and #1132 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Protagonist Therapeutics, Inc's MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Protagonist Therapeutics, Inc (CIK 1377121), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.